FDA Approves Second Once-Weekly Insulin for Type 2 Diabetes

The Food and Drug Administration approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin from Eli Lilly, for adults with type 2 diabetes, the agency said in an announcement dated September 24, 2026. According to the FDA, it is only the second once-weekly insulin ever approved for type 2 diabetes in the United States — a small but real shift in a drug class that has been built around daily injections for a century.

Onswik is a long-acting insulin analog meant to be injected under the skin once a week, on the same day each week, alongside diet and exercise, to help adults with type 2 diabetes control high blood sugar. The FDA is explicit that it is not recommended for type 1 diabetes, where the agency says it carries an increased risk of severe hypoglycemia. It is also not established as safe or effective in children.

What the trial record actually shows

The approval rests on four Phase 3 trials in the QWINT program, which together enrolled more than 3,400 adults with type 2 diabetes, according to Lilly’s own announcement of the approval. All four were randomized, open-label — meaning neither patients nor investigators were blinded to which insulin they received — and used an active comparator rather than a placebo: once-daily insulin glargine in some trials, once-daily insulin degludec in others. The FDA says each trial’s primary goal was to show that weekly efsitora was non-inferior to the daily comparator in lowering A1C, a blood test that reflects average blood sugar over roughly three months.

The four trials were not identical. QWINT-1 and QWINT-2 enrolled people who had never used insulin before and ran for 52 weeks. QWINT-3 enrolled people already on basal insulin and measured its primary result at 26 weeks inside a longer, 78-week trial. QWINT-4 enrolled people already on both basal and mealtime insulin, with mealtime insulin continued in both study arms, and measured its result at 26 weeks. In other words, the “comparable to daily insulin” finding was tested across several different patient populations and insulin regimens, not just one.

What neither the FDA’s announcement nor Lilly’s own release spells out is the actual size of the A1C difference between Onswik and the daily insulins — both describe the result only as “non-inferior” or “comparable,” without publishing the percentage-point numbers here. Lilly’s release points to the underlying trial results in the New England Journal of Medicine and The Lancet, but those figures are not part of either public announcement. That is a real gap for anyone trying to judge how the two options actually compare, not just whether one failed to be meaningfully worse than the other. The open-label design is standard for insulin-device trials, since patients can usually tell a once-weekly injection from a daily one, but it is still a limitation worth naming rather than glossing over.

Safety profile

The FDA describes Onswik’s overall safety profile in the trials as similar to the daily basal insulins it was compared against. The most common side effects listed are low blood sugar, allergic reactions, reactions at the injection site, lipodystrophy (changes in the fat tissue where injections are given), itching, rash, swelling, and weight gain. Hypoglycemia is flagged as the most common adverse reaction associated with insulin generally, including Onswik, and the FDA notes that severe episodes can cause seizures, loss of consciousness, or death.

The agency’s labeling also carries warnings for medication errors and accidental overdose — Onswik’s dosing works differently from other injectable diabetes drugs, so mixing it up matters — as well as for hypersensitivity reactions, low potassium levels, and fluid retention or heart failure risk when Onswik is combined with a class of diabetes pills called thiazolidinediones, or TZDs.

What’s still unknown

• Price has not been set publicly, and neither the FDA nor Lilly has disclosed it in these announcements.
• Lilly says the product will reach U.S. pharmacies “in the coming months,” without a firmer date.
• Insurance and Medicare coverage decisions, which typically follow separately from FDA approval, have not been addressed.
• Real-world results outside the trial setting — where adherence and monitoring are less controlled than in a clinical trial — are not yet available.

Onswik will be sold as a prefilled pen in two strengths, a lower-concentration and a higher-concentration version, according to Lilly, to accommodate different total weekly doses in a single injection.

Why it matters beyond one drug

Daily insulin injections are a well-documented barrier to starting and sticking with insulin therapy for people with type 2 diabetes — the FDA itself frames Onswik as reducing that day-to-day burden by design. A second once-weekly option on the U.S. market, rather than just one, gives prescribers and patients an actual choice between manufacturers rather than a single default, which matters for cost negotiation and formulary competition even before a price is announced. Whether that translates into better real-world blood sugar control, rather than just fewer needle sticks, is precisely the question the published A1C numbers — not yet public in these announcements — would need to answer.

Source: FDA, “FDA Approves Once-Weekly Insulin for Type 2 Diabetes Mellitus,” content dated September 24, 2026.

This article is general health information, not medical advice. Talk to a healthcare provider before starting or changing any insulin regimen.